- Home
- WFF vs GLTO Comparison
WFF vs GLTO Comparison
Compare WFF & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFF
- GLTO
- Stock Information
- Founded
- WFF 1984
- GLTO 2011
- Country
- WFF Malaysia
- GLTO Denmark
- Employees
- WFF N/A
- GLTO N/A
- Industry
- WFF Miscellaneous manufacturing industries
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- WFF Consumer Discretionary
- GLTO Health Care
- Exchange
- WFF Nasdaq
- GLTO Nasdaq
- Market Cap
- WFF 22.4M
- GLTO 23.7M
- IPO Year
- WFF 2025
- GLTO 2020
- Fundamental
- Price
- WFF $0.80
- GLTO $8.45
- Analyst Decision
- WFF
- GLTO Buy
- Analyst Count
- WFF 0
- GLTO 1
- Target Price
- WFF N/A
- GLTO $10.00
- AVG Volume (30 Days)
- WFF 129.9K
- GLTO 4.8M
- Earning Date
- WFF 11-24-2025
- GLTO 11-04-2025
- Dividend Yield
- WFF N/A
- GLTO N/A
- EPS Growth
- WFF N/A
- GLTO N/A
- EPS
- WFF 0.00
- GLTO N/A
- Revenue
- WFF $4,572,290.00
- GLTO N/A
- Revenue This Year
- WFF N/A
- GLTO N/A
- Revenue Next Year
- WFF N/A
- GLTO N/A
- P/E Ratio
- WFF $166.80
- GLTO N/A
- Revenue Growth
- WFF N/A
- GLTO N/A
- 52 Week Low
- WFF $0.75
- GLTO $2.01
- 52 Week High
- WFF $29.26
- GLTO $31.70
- Technical
- Relative Strength Index (RSI)
- WFF N/A
- GLTO 51.81
- Support Level
- WFF N/A
- GLTO $7.50
- Resistance Level
- WFF N/A
- GLTO $12.97
- Average True Range (ATR)
- WFF 0.00
- GLTO 2.52
- MACD
- WFF 0.00
- GLTO -0.50
- Stochastic Oscillator
- WFF 0.00
- GLTO 4.34
About WFF WF Holding Limited Ordinary Shares
WF Holding Ltd is a manufacturer of FRP products based in Malaysia. It has been providing high-quality and durable FRP products to various industries, including, among others, chemical processing, water and wastewater treatment, and power generation. Its products range from tanks, pipes, ducts, gratings and other custom-made FRP products. The company uses advanced production technology and equipment and has obtained various certifications. Its manufacturing capabilities allow the company to design and fabricate products that meet the specific needs of its clients, ensuring high-quality and reliable performance.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.